West Pharmaceutical Services (WST) On Daikyo Deal Looks Closer To Fully Valued
West Pharmaceutical Services (WST) has entered into two long-term distributorship agreements with Daikyo Seiko, granting West exclusive rights to distribute Daikyo products outside Japan and allowing Daikyo to distribute West products in Japan.
See our latest analysis for West Pharmaceutical Services.
At a share price of $352.32, West Pharmaceutical Services has seen a 30-day share price return of 7.43% and a 90-day share price return of 28.25%. The 1-year total shareholder return of 68.26% contrasts with slightly negative total shareholder returns over 3 and 5 years, which highlights a recent shift in performance as investors reassess growth potential and risks around deals such as the Daikyo partnership.
If this shift in sentiment has your attention, it could be a good moment to look beyond West and scan 39 healthcare AI stocks.
After the sharp rerating of West Pharmaceutical Services, the stock now sits close to the average analyst price target, while the modelled fair value points slightly lower. This raises the question of how much of the Daikyo deal is already reflected in today’s price.
Most Popular Narrative: 7% Undervalued
Compared with the last close at $352.32, the most followed narrative points to a fair value of $379, suggesting a modest valuation gap that hinges on how West Pharmaceutical Services executes on its higher value product mix and GLP 1 exposure.
The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could be a factor supporting revenue and earnings. The increase in demand and the transition to higher-margin HVP components, supported by approximately 340 Annex 1 projects, is described as likely to positively affect both revenue and net margins due to a favorable mix shift.
Want to see the full playbook behind that $379 figure? The narrative focuses on assumptions related to revenue trends, margins and a premium earnings multiple that are central to that valuation view.
Result: Fair Value of $379 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points for West Pharmaceutical Services, including potential demand shifts for high value components, as well as execution risk related to restructuring and leadership changes.
Find out about the key risks to this West Pharmaceutical Services narrative.
Another View: What Multiples Say About West Pharmaceutical Services
The earlier narrative leans on earnings forecasts and a fair value of $379, but current market multiples tell a tougher story for West Pharmaceutical Services. The stock trades on a P/E of 45.9x, compared with 38.1x for the Global Life Sciences industry and a fair ratio of 23x. This points to a high bar for execution and less room for error if expectations change.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals around West Pharmaceutical Services have you on the fence, now is a good time to review the data and firm up your stance, starting with the 2 key rewards.
Looking for more investment ideas beyond West Pharmaceutical Services?
If West Pharmaceutical Services has sharpened your thinking, do not stop here. Broaden your watchlist with other focused ideas that could sharpen your overall portfolio.
- Target resilient cash generators by checking out 45 high quality undervalued stocks that pair strong fundamentals with prices that may not fully reflect their financial profile.
- Strengthen your income stream by reviewing 9 dividend fortresses designed for investors who want yield supported by solid underlying businesses.
- Prioritize stability by scanning 80 resilient stocks with low risk scores so you can concentrate on companies with lower risk scores and potentially steadier fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com